{"id":"benralizumab-arm-c","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1742991","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benralizumab targets interleukin-5 receptor alpha (IL-5Rα), a key receptor on eosinophils and basophils that mediates their survival and activation. By blocking this receptor, the drug induces rapid eosinophil apoptosis and reduces circulating and tissue eosinophil populations. This mechanism effectively suppresses eosinophil-driven inflammatory responses in conditions like severe eosinophilic asthma.","oneSentence":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:53.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT02155660","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-25","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":2255}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benralizumab Arm C","genericName":"Benralizumab Arm C","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benralizumab Arm C was studied in a clinical trial for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history. The trial, NCT02155660, was conducted to evaluate the efficacy and safety of benralizumab in patients with COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}